Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Aino Health AB is a company that focuses on providing innovative corporate health management solutions. This Swedish organization offers systems designed to improve employee well-being, reduce sick leave, and enhance productivity across various industries. Central to its offerings is a comprehensive digital platform that helps businesses manage workforce health by integrating well-being initiatives, data analytics, and communication tools. Aino Health AB's solutions are crucial for companies aiming to foster a healthier work environment, thereby achieving better business outcomes. With its dedication to enhancing workplace wellness and efficiency, Aino Health AB plays a significant role in the growing market of health management services, catering to diverse sectors seeking sustainable operational success.
kr 0.00
+kr 0.00 (+0.00%)
EOD Jun 23, 2026 · Twelve Data
The business is unprofitable at the operating level (-20.13% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 9.1%, steady but not accelerating.
Negative free cash flow of -kr 2M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 24M
▲ +9.1% YoY
Net Income (TTM)
-kr 8M
▲ +38.4% YoY
Op. Margin
-28.24%
▲ +18.5pp YoY
ROIC
-99.80%
▲ +8811.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 5M
▲ +46.9% YoY
Op. Cash Flow (TTM)
-kr 5M
▲ +46.9% YoY
Net Debt
kr 3M
Cash & Equiv.
kr 6M
3Y CAGR: +9.5%
Continue Research
Aino Health AB (AINO.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Aino Health AB scores 26/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Aino Health AB scores 26 out of 100 on Intrinsiqq's quality score, passing 1 of 6 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -28.2% operating margin and a -99.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh AINO.XSTO's valuation and scores 26/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.